Journal article
TRICHOMONOSIS AND SUBSEQUENT RISK OF PROSTATE CANCER IN THE PROSTATE CANCER PREVENTION TRIAL
International journal of cancer, Vol.124(9), pp.2082-2087
05/01/2009
Handle:
https://hdl.handle.net/2376/103266
PMCID: PMC2682694
PMID: 19117055
Abstract
We previously observed a positive association between a history of trichomonosis, a sexually transmitted infection caused by the protozoan,
Trichomonas vaginalis
, and prostate cancer risk in the Health Professionals Follow-up Study. To determine the reproducibility of this finding, we conducted a second, prospective investigation of trichomonosis and prostate cancer in the Prostate Cancer Prevention Trial. Participants were men ≥55 years of age with no evidence of prostate cancer at enrollment (n=18,882). Men were screened annually for prostate cancer, and if not diagnosed during the trial, were offered an end-of-study prostate biopsy. Cases were a sample of men diagnosed with prostate cancer on any biopsy after visit 2 or on their end-of-study biopsy (n=616). Controls were men not diagnosed with prostate cancer during the trial or on their end-of-study biopsy (n=616). Controls were frequency-matched to cases by age, treatment arm, and family history of prostate cancer. Serum from visit 2 was tested for anti-
T. vaginalis
IgG antibodies. No association was observed between
T. vaginalis
serostatus and prostate cancer. 21.5% of cases and 24.8% of controls had low seropositivity, and 15.2% and 15.0% had high seropositivity. Compared to seronegative men, the odds ratio of prostate cancer for men with low seropositivity was 0.83 (95% confidence interval (CI): 0.63–1.09), and that for men with high seropositivity was 0.97 (95% CI: 0.70–1.34). Given the original strong biologic rationale and potential for prevention, additional studies are warranted to help resolve discrepancies between study findings, and further investigate this hypothesis from a variety of different approaches.
Metrics
13 Record Views
Details
- Title
- TRICHOMONOSIS AND SUBSEQUENT RISK OF PROSTATE CANCER IN THE PROSTATE CANCER PREVENTION TRIAL
- Creators
- Siobhan Sutcliffe - Alvin J. Siteman Cancer Center and the Department of Surgery, Washington University School of Medicine, St. Louis, MOJohn F Alderete - School of Molecular Biosciences, Fulmer Hall, Washington State University, Pullman, WACathee Till - Fred Hutchinson Cancer Research Center, Seattle, WAPhyllis J Goodman - Fred Hutchinson Cancer Research Center, Seattle, WAAnn W Hsing - Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MDJonathan M Zenilman - Division of Infectious Diseases, Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, MDAngelo M De Marzo - Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MDElizabeth A Platz - James Buchanan Brady Urological Institute and the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, Baltimore, MD
- Publication Details
- International journal of cancer, Vol.124(9), pp.2082-2087
- Academic Unit
- Molecular Biosciences, School of
- Identifiers
- 99900546793201842
- Language
- English
- Resource Type
- Journal article